Skip to main content

Advertisement

SpringerLink
Log in

Insulin Prevents Latent Skin Lesions by Inhibiting the Generation of Advanced Glycation End Products in Streptozotocin-Induced Diabetic Rats

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

The preventive effect of insulin on latent skin lesions in streptozotocin-induced diabetic rats was investigated. Diabetes was induced in 72 male Sprague–Dawley rats, with 36 rats serving as the control group. Half of the diabetic rats were treated with insulin, and the other half were injected with vehicle. Skin tissues were collected 4, 8, and 12 weeks after the initiation of insulin therapy for measurement of glucose, collagen-related fluorescence and advanced glycation end product (AGE) expression, and histological observation. The diabetic rats exhibited changes in skin tissue, including a decrease in thickness, disappearance of the multilayer epithelium structure, degeneration of collagen fibers, and an increase in the infiltration of inflammatory cells, in addition to a significant increase in blood glucose and AGE expression. These effects were greatly ameliorated by insulin therapy. Insulin therapy in early-stage diabetes mellitus prevents potential skin lesions, possibly by inhibiting AGE formation and inflammatory reactions following glycemic control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Wertheimer E. Diabetic skin complications: a need for reorganizing the categories of diabetes-associated complications. Israel Med Assoc J 6:287–9, 2004.

    Google Scholar 

  2. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care 24:1019–22, 2001. doi:10.2337/diacare.24.6.1019.

    Article  PubMed  CAS  Google Scholar 

  3. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 3:513–21, 1990. doi:10.2337/diacare.13.5.513.

    Article  Google Scholar 

  4. Bloomgarden ZT. The Diabetic Foot. Diabetes Care 31:372–6, 2008. doi:10.2337/dc08-zb02.

    Article  PubMed  Google Scholar 

  5. Brooks BA, McLennan SV, Twigg SM, Yue DK. Detection and characterisation of microcirculatory abnormalities in the skin of diabetic patients with microvascular complications. Diab Vasc Dis Res 5:30–5, 2008. doi:10.3132/dvdr.2008.006.

    Article  PubMed  Google Scholar 

  6. Jaap AJ, Pym CA, Seamark C, Shore AC, Tooke JE. Microvascular function in type 2 (non-insulin-dependent) diabetes: improved vasodilation after one year of good glycaemic control. Diabetic Med 12:1086–91, 1995.

    Article  PubMed  CAS  Google Scholar 

  7. Cavallini M. Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Rrepair Regen 15:35–8, 2007. doi:10.1111/j.1524-475X.2006.00182.x.

    Article  Google Scholar 

  8. Lutgers HL, Graaff R, Links TP, Ubink-Veltmaat LJ, Bilo HJ, Gans RO, Smit AJ. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 9:2654–9, 2006. doi:10.2337/dc05-2173.

    Article  Google Scholar 

  9. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications: DCCT Skin Collagen Ancillary Study Group: Diabetes Control and Complications Trial. Diabetes 48:870–80, 1999. doi:10.2337/diabetes.48.4.870.

    Article  PubMed  CAS  Google Scholar 

  10. Tabor CA, Parlette EC. Cutaneous manifestations of diabetes. Signs of poor glycemic control or new-onset disease. J Postgra Med 119:38–44, 2006.

    Google Scholar 

  11. Kurcer Z, Parlakpinar H, Vardi N, Tasdemir S, Iraz M, Fadillioglu E, Baba F, Gül M. Protective effects of chronic melatonin treatment against renal ischemia/reperfusion injury in streptozotocin-induced diabetic rats. Exp Clin Endocr Diab 115:365–71, 2007. doi:10.1055/s-2007-971056.

    Article  CAS  Google Scholar 

  12. Kun Hwang, Dae Joong Kim, Se Ho Hwang. Thickness of Korean upper eyelid skin at different levels. J Craniofac Surg 17(1):54–6, 2006. doi:10.1097/01.scs.0000188347.06365.a0.

    Article  Google Scholar 

  13. Bannai C, Yamazaki M, Matsushima Y, Kunika K, Itakura M, Okuda Y, Yamashita K. Amelioration of dermal lesions in streptozotocin-induced diabetic rats by aminoguanidine. Diabetes Res 20:87–95, 1992.

    PubMed  CAS  Google Scholar 

  14. Sajithlal GB, Chithra P, Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochem Pharmacol 56:1607–14, 1998. doi:10.1016/S0006-2952(98)00237-8.

    Article  PubMed  CAS  Google Scholar 

  15. Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pr 67: 3–21, 2005. doi:10.1016/j.diabres.2004.09.004.

    Article  CAS  Google Scholar 

  16. Jelinek JE. The skin in diabetes. Diabetic Med 10: 201–13, 1993.

    Article  PubMed  CAS  Google Scholar 

  17. Mulder DJ, Water TV, Lutgers HL, Graaff R, Gans RO, Zijlstra F, Smit AJ. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. Diabetes Technol Ther 8:523–35, 2006. doi:10.1089/dia.2006.8.523.

    Article  PubMed  CAS  Google Scholar 

  18. Ahmed N, Thornalley PJ. Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9:233–45, 2007. doi:10.1111/j.1463-1326.2006.00595.x

    Article  PubMed  CAS  Google Scholar 

  19. Sajithlal GB, Chithra P, Chandrakasan G. Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta 1407:215–24, 1998.

    PubMed  CAS  Google Scholar 

  20. Hammes HP, Weiss A, Hess S, Araki N, Horiuchi S, Brownlee M, Preissner KT. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. Lab Invest 75:325–38, 1996.

    PubMed  CAS  Google Scholar 

  21. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG. Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260–9, 2002. doi:10.1210/en.143.4.1260

    Article  PubMed  CAS  Google Scholar 

  22. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes 55:2245–55, 2006. doi:10.2337/db05-1375.

    Article  PubMed  CAS  Google Scholar 

  23. Bitar MS. Glucocorticoid dynamics and impaired wound healing in diabetes mellitus. Am J Pathol 152: 547–54, 1998.

    PubMed  CAS  Google Scholar 

  24. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 14:558–65, 2006. doi:10.1111/j.1743-6109.2006.00155.x.

    Article  PubMed  Google Scholar 

  25. Ahmed I, Goldstein B. Diabetes mellitus. Clin Dermatol 24:237–46, 2006. doi:10.1016/j.clindermatol.2006.04.009

    Article  PubMed  Google Scholar 

  26. Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skin keratinocytes: implications for diabetes skin complications. Diabetes 50: 1627–35, 2001. doi:10.2337/diabetes.50.7.1627

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank Dr. Hui Zhang and Libin Zhang for helpful discussions. This research was supported by grants from the Shanghai Science and Technology Commission’s Program for Key Basic Research (No. 08JC1407200) and the National Program for Key Basic Research Projects (No. 2005CB523304).

Author information

Authors and Affiliations

  1. Department of Endocrinology, Chang Zheng Hospital, Second Military Medical University, Shanghai, 200003, China

    Xiangfang Chen, Yongquan Shi, Junjie Zou & Zhimin Liu

  2. Department of Burns, Shanghai Fire Corps Hospital Chinese People’s Armed Police, Shanghai, 200443, China

    Weidong Lin

  3. Shanghai Burns Institute, Burns Department of Ruijin Hospital, Jiaotong University, Shanghai, 20025, China

    Shuliang Lu

  4. Department of Dermatology, Chang Zheng Hospital, Second Military Medical University, Shanghai, 200003, China

    Wanqing Liao

Authors
  1. Xiangfang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weidong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuliang Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yongquan Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Junjie Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhimin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wanqing Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhimin Liu or Wanqing Liao.

Additional information

Xiangfang Chen and Weidong Lin contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, X., Lin, W., Lu, S. et al. Insulin Prevents Latent Skin Lesions by Inhibiting the Generation of Advanced Glycation End Products in Streptozotocin-Induced Diabetic Rats. Endocr Pathol 20, 163–169 (2009). https://doi.org/10.1007/s12022-009-9084-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-009-9084-0

Keywords

Search

Navigation